NEAUA Main Site   | Past & Future Meetings
The New England Section of the American Urological Association
Meeting
Home
Accreditation
Information
Preliminary
Program
Registration
Information
Housing
Information
Exhibitors &
Sponsors
Local Area
Attractions

Back to 2016 Annual Meeting


Emerging Data Regarding Trends in Surgical Education and Research Financial Relationships Between Device Manufacturers and Prosthetic Urologists
Martin S. Gross, MD1, Gerard D. Henry, MD2.
1Dartmouth-Hitchcock Medical Center/Dartmouth-Hitchcock Keene, Keene, NH, USA, 2Regional Urology, Shreveport, LA, USA.

BACKGROUND: The Affordable Care Act mandates manufacturer reporting of financial relationships with physicians and hospitals. The first year of data regarding Open Payments for 2014 is available via the Center for Medicare and Medicaid Services (CMS) website. We explored the financial relationships between the primary prosthetic urology device manufacturers, American Medical Systems (now Boston Scientific) and Coloplast, and the male health urologic surgeons with whom they have financial relationships specific to payments for surgical education and research.
METHODS: A review of the CMS Open Payments data was performed. Payment information was separated into general payments and research payments. The top 25 surgeons were compiled from each of the two device manufacturers. Surgeons who primarily implant female devices were removed from the list as other device manufacturers also provide these products. We then selected the male health urologic surgeons (i.e. high-volume implanters of inflatable penile prostheses, male slings, and artificial urinary sphincters) for further detailed analysis.
RESULTS: AMS distributed approximately $2,588,908 in general payments to the top 25 prosthetic urologists on its list, $1,852,715 to 19 male health surgeons. Coloplast distributed approximately $2,702,278 in general payments to the top 25 prosthetic urologists on its list, $1,988,184 to 16 male health surgeons. AMS distributed a total of $333,371 in research payments, with $167,163 towards male health-related clinical trials. Coloplast distributed $246,278 in research payments, with $18,787 towards male health-related clinical trials. The top five male health surgeons for AMS accrued a total of $920,974 in payments (mean $184,194). The top five male health surgeons for Coloplast accrued a total of $1,522,302 in payments (mean $304,460). Four surgeons were in the top 25 for both manufacturers, with one in the top ten for both.
CONCLUSIONS: CMS Open Payments data allow for a transparent view of the financial relationships between prosthetic urologists and industry. Coloplast has a smaller market share in inflatable penile prostheses and male continence devices than AMS, but they distribute more money to prosthetic urologists for surgical education. AMS research funding appears to be directed towards IPP-related clinical trials, while Coloplast funding is directed towards male sling trials. There is a top-heavy distribution of payments by Coloplast, with the first five surgeons receiving substantially more funding on average than those for AMS.


Back to 2016 Annual Meeting


Old Port
Bay by Holiday Inn
Lighthouse
© 2022 New England Section of the American Urological Association. All Rights Reserved. Privacy Policy.
Banner photo courtesty of Holiday Inn By the Bay © InterContinental Hotels.